OstEvo - Osteosarcoma Evolves
Memorial Sloan Kettering Cancer Center
Summary
The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.
Eligibility
- Age range
- 6–49 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: Cohort 1 only: Newly Diagnosed, Metastatic Osteosarcoma 1. For study entry, the suspected diagnosis of osteosarcoma may be based on clinical judgement. Biopsy confirmation is required for treatment but as this protocol has biologic aims from serial tumor samples, some patients will be enrolled prior to open biopsy. Patients must have a histologic new diagnosis of metastatic high-risk osteosarcoma to start OstEvo systemic therapy. For purposes of this protocol, newly diagnosed, high-risk metastatic osteosarcoma includes: 1. Having at least 1 extrapulmonary metastasis,…